Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
04/2012
04/05/2012US20120083511 Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol
04/05/2012US20120083504 Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof
04/05/2012US20120083503 Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
04/05/2012US20120083502 Heterocyclic compounds and their uses
04/05/2012US20120083499 Novel benzenesulfonamides as calcium channel blockers
04/05/2012US20120083496 Isoxazole compound for the treatment of cancer
04/05/2012US20120083495 Compounds for the treatment of spinal muscular atrophy and other uses
04/05/2012US20120083494 Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors
04/05/2012US20120083492 Imidazopyrazines for use as kinase inhibitors
04/05/2012US20120083488 Tetracyclic compound
04/05/2012US20120083484 Cyclopamine lactam analogs and methods of use thereof
04/05/2012US20120083482 Inhibitors of vegf receptor and hgf receptor signaling
04/05/2012US20120083477 Proteasome inhibitors and uses thereof
04/05/2012US20120083476 Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
04/05/2012US20120083470 Inhibitors of tyrosine kinases and uses thereof
04/05/2012US20120083459 Use of ganglioside to decrease propagation of malignant prostate cells
04/05/2012US20120083455 HYMAN SERUM ALBUMIN-siRNA NANO-SIZED CARRIER SYSTEM
04/05/2012US20120083454 Eph receptor expression in tumor stem cells
04/05/2012US20120083442 Myostatin binding agents
04/05/2012US20120083440 Methods and compounds for the targeted delivery of agents to bone for interaction therewith
04/05/2012US20120082736 Small-molecule TNF modulator to reduce the side effects of chemotherapy and radiotherapy
04/05/2012US20120082732 Medicine for treatment of a carcinoma
04/05/2012US20120082729 Quick dissolve compositions and tablets based thereon
04/05/2012US20120082728 Multifunctional stealth nanoparticules for biomedical use
04/05/2012US20120082725 Composition Comprising Immunogenic Microparticles
04/05/2012US20120082722 Methods and compositions for oral delivery of fts
04/05/2012US20120082717 Complex, multilayer using the same, and device coated with the multilayer
04/05/2012US20120082716 Cytotoxic agents
04/05/2012US20120082706 Medical device for drug delivery
04/05/2012US20120082703 Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals
04/05/2012US20120082702 Nicotinamide compounds useful as kinase modulators
04/05/2012US20120082701 Polarized scorpion venom solution and a method for making polarized scorpion venom solution
04/05/2012US20120082699 Method of Producing Rough Strains of Bacteria and Uses Thereof
04/05/2012US20120082696 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
04/05/2012US20120082691 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
04/05/2012US20120082689 Method of treatment an oncological disease
04/05/2012US20120082687 Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
04/05/2012US20120082686 Neovascular-Targeted Immunoconjugates
04/05/2012US20120082683 Superagonistic Anti-CD28 Antibodies
04/05/2012US20120082682 Il-13 binding protein
04/05/2012US20120082675 Insulin-like growth factor signaling and integrin
04/05/2012US20120082673 Human cytokine receptor
04/05/2012US20120082670 Cd33 binding agents
04/05/2012US20120082664 Optimized antibodies that target cd19
04/05/2012US20120082663 Anti-cmet antagonists
04/05/2012US20120082662 Anti-cmet antagonists
04/05/2012US20120082661 Anti-bcma antibodies
04/05/2012US20120082659 Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
04/05/2012US20120082655 Downregulation of SPY1 by p53 as an essential component of p53-mediated effects
04/05/2012US20120082647 Interferon-beta for use as monotherapy or in combination with other cancer therapies
04/05/2012US20120082643 Compositions and Methods for Modulating a Cytotoxic T Lymphocyte Immune Response
04/05/2012US20120082640 Small molecule apoptosis promoters
04/05/2012US20120082636 Stabilized alpha helical peptides and uses thereof
04/05/2012US20120082635 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
04/05/2012US20120082621 Swallowtail motifs for imparting water solubility to porphyrinic compounds
04/05/2012US20120082618 Prostate cancer diagnosis and treatment
04/05/2012CA2813304A1 Interferon-beta for use as monotherapy or in combination with other cancer therapies
04/05/2012CA2813256A1 Aryl-substituted imidazoles
04/05/2012CA2813253A1 Method of preparing a dry powder from a water bacteria extract-concentrate
04/05/2012CA2813203A1 Anti-human ccr7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
04/05/2012CA2813133A1 Anti-ceacam6 antibodies and uses thereof
04/05/2012CA2813069A1 Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
04/05/2012CA2812859A1 Phenylquinazoline derivatives
04/05/2012CA2812790A1 Therapeutic use of a tlr agonist and combination therapy
04/05/2012CA2812756A1 Antibody against human prostaglandin e2 receptor ep4
04/05/2012CA2812753A1 Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
04/05/2012CA2812750A1 Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
04/05/2012CA2812744A1 Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
04/05/2012CA2812631A1 Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
04/05/2012CA2812460A1 Amatoxin-conjugates with improved linkers
04/05/2012CA2812057A1 Compositions and methods for treatment of hematological malignancies
04/05/2012CA2811934A1 7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as ccr2 receptor antagonists
04/05/2012CA2811667A1 Thiazolidine linker for the conjugation of drugs to antibodies
04/04/2012EP2436762A1 Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
04/04/2012EP2436680A2 Chroman derivatives, medicaments and use in therapy
04/04/2012EP2436676A1 Human adam-10 inhibitors
04/04/2012EP2436399A1 Polymeric nano-particles for siRNA delivery using charge interaction and covalent bonding
04/04/2012EP2436398A1 Amatoxin-conjugates with improved linkers
04/04/2012EP2436397A1 Pharmaceutical composition containing antagonist of egf family ligand as component
04/04/2012EP2436382A1 Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitor chelate complexes
04/04/2012EP2436376A1 Cancer cell targeting using nanoparticles
04/04/2012EP2435570A1 Differentiation therapy for sarcomas
04/04/2012EP2435567A1 Cdc45l peptides and vaccines including the same
04/04/2012EP2435478A1 Antigen-binding proteins
04/04/2012EP2435469A1 Casb7439 constructs
04/04/2012EP2435463A2 Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them
04/04/2012EP2435445A1 Inhibitors of c-met protein kinase
04/04/2012EP2435444A1 Substituted pyrazole inhibitors of c-met protein kinase
04/04/2012EP2435443A1 Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase
04/04/2012EP2435438A1 Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
04/04/2012EP2435436A1 Pyrimidine inhibitors of kinase activity
04/04/2012EP2435435A1 Pyrimidine inhibitors of kinase activity
04/04/2012EP2435430A1 Substituted 3-(1,2,4-oxadiazol-5-yl)-5-phenylpiperidines
04/04/2012EP2435426A1 BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE
04/04/2012EP2435423A1 Substituted benzotriazines and quinoxalines as inhibitors of p7os6 kinase
04/04/2012EP2435412A1 Disaccharin, difumaric acid, di-l-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamin0)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin- 5 -yl) methyl) phenyl)acetate
04/04/2012EP2435411A1 2, 4 -diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
04/04/2012EP2435405A1 Substituted piperidines
04/04/2012EP2435076A1 Anti-ck8 antibodies to be used for treating colorectal cancers and identifying metastatic and/or invasive phenotypes
04/04/2012EP2435068A2 Use of 2 anti-sparc antibodies to predict response to chemotherapy
1 ... 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 ... 2211